| P569 | Novel Pharmacobiotic approach to enhance the tamoxifen efficacy using bacterial extracellular vesicles as the immunotherapy in breast cancer | Jeongshin An, MD,Ph.D; Yeun-yeoul Yang; Won-Hee Lee; Jinho Yang; Jong-kyu Kim; HyunGoo Kim; Se Hyun Paek; Jun Woo Lee; Joohyun Woo; Jong Bin Kim; Hyungju Kwon; Woosung Lim; Nam Sun Paik; Yoon-Keun Kim; Byung-In Moon; | Tumor microenvironment |
| P570 | Commensal bacteria Bifidobacterium stimulates an anti-tumor response via cross-reactivity. | Catherine A. Bessell, BA; Ariel Y. Isser; Jonathan Havel, PhD; Sangyun Lee, PhD; Ruhong Zhou, PhD; Timothy A. Chan, MD, PhD; Jonathan P. Schneck, MD, PhD; David Bell, PhD | Adoptive immunotherapy; Microbiome; Neoantigens; T cell |
| P571 | Targeted sequencing of 16s rRNA Gene to understand the diversity and composition of the gut microbiome | Jianping Zheng; Karen L. Clyde, PhD; Fiona Hyland; Janice Au-Young, PhD; Rajesh K. Gottimukkala, MS; Asha Kamat, PhD; | Bioinformatics; Biomarkers; Checkpoint blockade; Microbiome |
| P572 | Variation of the gut microbiome of complete responders to immune checkpoint blockade and healthy individuals – implications for clinical trial design | Beth Helmink, MD PhD; Vancheswaran Gopalakrishnan, MPH, PhD; Abdul Wadud Khan, MD; Pierre-Olivier Gaudreau; Elizabeth Sirmans; Elizabeth Burton; Vanessa B. Jensen, DVM; Adrienne F. Duran, B.A.S.; Linsey Martin; Angela L. Harris; Miles Andrews, MD, PhD; Jennifer L. McQuade, MD; Alexandria P. Cogdill, MEng; Christine N. Spencer, PhD; Reetakshi Arora; Nadim Ajami, PhD; Joseph Petrosino, PhD; Jamal A. Mohamed; Sapna Patel, MD; Michael K. Wong, MD PhD FRCPC; Rodabe N. Amaria, MD; Jeffrey E. Gershenwald, MD; Patrick Hwu, MD; Wen-Jen Hwu, MD, PhD; Michael Davies, MD, PhD; Isabella C. Glitza, MD, PhD; Hussein A. Tawbi, MD, PhD; George Marnellos; Jaclyn Sceneay; Jennifer Wortman; Lata Jayaraman; David Cook; Theresa LaVallee; Robert Jenq, MD; Timothy Heffernan, PhD; Jennifer A. Wargo, MD, MMSc; | Clinical trial; Microbiome; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P573 | Antibiotic use and clinical outcomes of PD-1 antagonists in advanced non-small cell lung cancers | Amit Kulkarni, MD; Manish R. Patel, DO; Ying Wang, MD, Ph.D.; Todd Defor, MS | Checkpoint blockade; Clinical study; Microbiome; Solid tumors |
| P574 | A rationally-designed consortium of human gut commensals induces CD8 T cells and modulates host anti-cancer immunity | Takeshi Tanoue; Satoru Morita; Koji Atarashi; Wataru Suda; Damian Plichta; Seiko Narushima; Ashwin Skelly; Atsushi Shiota; Jason Norman; Vanni Bucci; Yutaka Kawakami, MD PhD; Masahira Hattori; Ramnik Xavier; Bernat Olle; Bruce L. Roberts, PhD; Kenya Honda, MD, PhD | Checkpoint blockade; Microbiome; T cell; Tumor infiltrating lymphocytes (TILs) |
| P575 | Classification of the human gut microbiome using a validated 16S rRNA next generation sequencing method | Janet Doolittle-Hall; Melissa Howard; Jennifer K. Sims; Scott Yourstone; Jason Powers; Patrick Hurban, PhD; Victor J. Weigman, Jr. | Microbiome |
